Home » Interviews » INTERVIEW: Widecells Group Plc Two product launches with massive potential
WideCells Group

INTERVIEW: Widecells Group Plc Two product launches with massive potential

Widecells Group Plc (LON:WDC) Chief Executive Officer, João Andrade and Chief Scientific Officer Dr Peter Hollands join DirectorsTalk to discuss two product launches. João explains how the CellPlan e-commerce platform works, the impact this will have on sales and revenue and how they will target a much wider audience. Peter provides us with some detail on his background, why he chose to work with Widecells, what the second product INDUS is, how it will be used and roll out plans.

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. In June 2017, the Group was ranked as the 21st most disruptive company globally by DISRUPT 100, an annual index celebrating the businesses with the most potential to influence, change or create new global markets.

With this in mind, it has created three divisions:

· CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process

· WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.

· WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

You might also find these articles of interest:

Register here to be notified of future articles like this
Get all our broker ratings on Twitter as they are published!